Summary
Cannot be accurately assessed because the provided prompt does not include the AI-generated response text to compare; only a list of claims is provided. Additionally, several claims are too general to be mapped to the supplied label excerpts, and the label excerpts omit required elements for a full check (e.g., boxed warning status, administration instructions beyond taking with food).
Category Scores
Accurate Statements
Unsupported Statements
Nitrofurantoin is an antibiotic used to treat certain bacterial urinary tract (UTI) infections.
The supplied label excerpt includes an indication for acute uncomplicated urinary tract infections caused by susceptible strains, but no explicit evidence was provided that this exact phrasing is supported; also label information provided is limited to a narrow indication (acute uncomplicated cystitis), making the broad UTI framing not directly verifiable from the provided excerpts.
Nitrofurantoin is used particularly for infections limited to the bladder (cystitis) rather than kidney infections (pyelonephritis).
The label excerpt states it is not indicated for pyelonephritis or perinephric abscesses and is indicated for acute uncomplicated UTIs (acute cystitis). However, the claim’s wording about 'particularly' and 'rather than' kidney infections is not directly quoted; mapping is partially supported but not exact.
Nitrofurantoin targets bacteria responsible for common uncomplicated UTIs.
The label excerpt specifies susceptible strains of E. coli or S. saprophyticus for acute uncomplicated acute cystitis, but the claim is general ('common uncomplicated UTIs') and not directly supported by the provided excerpt.
Nitrofurantoin is designed to kill bacteria in the urinary tract.
No mechanism language ('kill bacteria') is provided in the excerpts.
After reaching the urine, nitrofurantoin becomes active against susceptible bacteria.
No phrase supporting 'after reaching the urine becomes active' is provided in the supplied excerpts.
Nitrofurantoin helps clear infection in the bladder.
The label excerpt includes microbiologic eradication but does not explicitly state 'helps clear infection in the bladder' in that form.
Nitrofurantoin is commonly available in tablet forms.
The provided label excerpts and identified formulation reference capsules (monohydrate/macrocrystals capsules). No tablet availability statement is supported by the provided label excerpts.
Nitrofurantoin includes formulations intended for better tolerability and consistent release.
No label excerpt provided states improved tolerability or consistent release as an intended formulation purpose.
The exact product and dosing schedule depend on the specific nitrofurantoin formulation prescribed.
The label excerpt provided gives a specific dosing regimen for nitrofurantoin monohydrate/macrocrystals capsules; it does not support a general statement about dosing varying by formulation beyond what is shown.
The dose and length of treatment with nitrofurantoin depend on the infection type, the specific nitrofurantoin formulation, and the patient’s situation (including kidney function).
The label excerpt includes a fixed adult/pediatric (over 12 years) regimen for the indicated condition and includes renal function contraindications, but it does not support 'depends on infection type' and 'length depends' in the generalized way stated.
Taking nitrofurantoin exactly as prescribed and finishing the full course is important to reduce the chance of treatment failure or recurrence.
No adherence/counseling statement is included in the provided label excerpts.
For uncomplicated bladder infections, nitrofurantoin treatment courses are often short (commonly a few to several days).
The label excerpt provides a 7-day regimen for adults and pediatric patients over 12 years; it does not support 'often' or 'few to several days' generically.
The duration of nitrofurantoin treatment depends on the regimen selected by the prescriber and the patient’s response.
The provided dosage excerpt specifies a 7-day regimen; no label excerpt supports variability based on prescriber selection or patient response.
Nitrofurantoin is generally avoided when it is not expected to reach effective levels in urine.
The label excerpt states contraindications related to significant renal impairment but does not provide the generalized 'not expected to reach effective levels' wording.
Nitrofurantoin is generally avoided when a kidney infection is suspected.
The label excerpt states it is not indicated for pyelonephritis/perinephric abscesses, but does not provide a 'generally avoided when suspected' counseling statement.
Reduced kidney clearance can limit urinary antibiotic levels and increase the risk of side effects from nitrofurantoin.
The label excerpt states increased risk of toxic reactions in impaired renal function and provides rationale related to urinary levels/serum levels in the drug interaction section; however, 'can limit urinary antibiotic levels and increase risk of side effects' is not directly stated as such in the provided excerpts.
Nitrofurantoin can cause gastrointestinal side effects such as nausea.
The label excerpt supports nausea (8%) but does not support 'can cause GI side effects such as nausea' as a specific unquoted paraphrase; it is likely supported but not explicitly verifiable from the excerpt language beyond nausea.
Nitrofurantoin can cause headache or mild dizziness.
The label excerpt supports headache (6%) and dizziness as selected events, but the 'mild' qualifier is not supported.
Nitrofurantoin can cause changes in urine color, often darker.
No urine color change information is included in the provided adverse reactions excerpts.
Nitrofurantoin can cause allergic reactions with signs such as swelling of the face or throat and trouble breathing.
The label excerpts mention hypersensitivity/pulmonary hypersensitivity but do not provide these specific symptom examples.
Nitrofurantoin can cause severe skin reactions.
The provided label excerpts include severe skin reactions? No specific wording or examples for 'severe skin reactions' are included.
Nitrofurantoin can cause symptoms that suggest lung problems, such as persistent cough and shortness of breath.
The label excerpts mention acute pulmonary hypersensitivity reactions and pulmonary reactions, but do not list persistent cough or shortness of breath as examples.
Nitrofurantoin can cause symptoms that suggest liver problems, such as jaundice and severe fatigue.
The label excerpt supports hepatic reactions including cholestatic jaundice, and mentions fatal hepatic necrosis, but does not provide 'severe fatigue' specifically.
Use of nitrofurantoin in pregnancy depends on gestational age and overall risk-benefit.
The provided label excerpts include contraindication in pregnant patients at term (38–42 weeks) and not labor imminent, but do not provide a generalized 'depends on gestational age and overall risk-benefit' statement.
Use of nitrofurantoin while breastfeeding depends on infant age and overall risk-benefit.
No breastfeeding-specific label excerpt was provided.
Clinicians weigh the need to treat a UTI promptly against risk when considering nitrofurantoin in pregnancy or breastfeeding.
No such counseling/risk-benefit weighing statement is included in the provided excerpts.
Untreated UTIs can lead to complications.
No statement about consequences of untreated UTIs is included in the provided label excerpts.
Drug interactions with nitrofurantoin depend on the specific medicines involved.
The label excerpt lists specific interaction examples but does not support this general statement as labeled text.
Certain drug combinations with nitrofurantoin can raise the risk of side effects or reduce effectiveness.
The label excerpt supports reduced absorption with certain antacids and reduced urinary levels/lessened efficacy with probenecid/sulfinpyrazone, and increased serum levels increasing toxicity. This paraphrase is likely consistent but not directly quoted in the supplied excerpt language beyond those general effects.
Patients should tell their clinician and pharmacist about all medications, including over-the-counter products and supplements, before starting nitrofurantoin.
No patient counseling statement of this type is included in the provided label excerpts.
If symptoms do not improve within the expected timeframe on nitrofurantoin, the lack of response can signal resistance.
No statement about resistance detection based on symptom response is included in the provided label excerpts.
If symptoms do not improve within the expected timeframe on nitrofurantoin, lack of response can signal an infection type outside nitrofurantoin’s typical target, such as kidney involvement.
The label indicates it is not indicated for pyelonephritis/perinephric abscesses, but no statement ties lack of response timing to infection type.
If symptoms do not improve within the expected timeframe on nitrofurantoin, lack of response can indicate the need for a different antibiotic.
No such guidance is included in the provided excerpts.
For infections suggesting kidney involvement, clinicians often choose antibiotics that better treat kidney tissue rather than relying on nitrofurantoin.
While label says not indicated for pyelonephritis/perinephric abscesses, no guidance about clinicians choosing other antibiotics is provided in the excerpts.
Nitrofurantoin is widely available as a generic medication in many countries.
No availability/generic market statement is included in the provided label excerpts.
Generic nitrofurantoin usually means similar active ingredient and dosing to brand-name products.
No regulatory equivalence/market statement is included in the provided label excerpts.
Specific brand names and formulations of nitrofurantoin vary by market.
No market/brand statement is included in the provided label excerpts.
Nitrofurantoin formulations may include 'macrocrystals' and 'monohydrate'.
This is consistent with the provided label excerpt and identified formulation, but it is not evaluated against AI response text because no full AI response paragraph is provided; still, the concept is supported by the label excerpt language 'two forms... [macrocrystalline/monohydrate]' as consistent.
Contradictions
Important Omissions
Boxed warnings status and content (if any) for nitrofurantoin.
Importance:
Moderate
Explicit contraindications details: anuria/oliguria, significant renal impairment thresholds (CrCl <60 mL/min or elevated serum creatinine), cholestatic jaundice/hepatic dysfunction history, hypersensitivity, and term pregnancy/neonates under 1 month.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple non-label-supported generalized claims are made (e.g., formulation intent/tolerability, urine color, specific symptom examples, generic availability, and mechanistic 'after reaching urine becomes active') without support from the provided label excerpts; additionally, key contraindication specifics and administration caveats beyond 'with food' cannot be verified from the provided excerpts and may be omitted depending on what the AI response actually said.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Most statements are either too general or not directly supported by the provided label excerpts; key labeled details (exact contraindication thresholds and some labeled administration/precaution specifics) are not verifiably covered in the supplied material.
Suggested Improvement
Constrain claims to the exact FDA label wording provided (indication limited to acute uncomplicated cystitis due to susceptible strains; not indicated for pyelonephritis/perinephric abscesses; provide labeled adult dosing 100 mg q12h x 7 days and 'take with food'; use label-supported adverse events (nausea, headache, flatulence) and labeled warnings/precautions without adding symptom examples not in the excerpts; include contraindication details verbatim from the label excerpts where applicable; omit market/generic availability statements unless present in the label.